Urokinase plasminogen activator: A prognostic marker in breast cancer including patients with axillary node-negative disease

Clinical Chemistry

Volumn 44, Issue 6, 1998, Pages 1177-1183

  Duffy, Michael J ^a   Duggan, Catherine ^a   Mulcahy, Hugh E ^b   McDermott, Enda W ^a   O'Higgins, Niall J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; TREATMENT PLANNING;

EID: 0031778389     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.6.1177     Document Type: Article

References (25)

1. Borling CC, Squires TS, Tong T. Cancer Statistics CA. Cancer J Clin 1992;42:19-32.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 331,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
3. McGuire WL, Clark CM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992;326:1756-61.
4. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8(Suppl 1):189-203.
5. Duffy MJ. Urokinase plasminogen activator and malignancy. Fibrinolysis 1993;7:295-302.
6. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-18.
7. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600.
8. Duffy MJ, O'Siorain L, Waldron B, Smith C. Estradiol receptors in human breast carcinomas assayed by the use of monoclonal antibodies. Clin Chen 1986;32:1972-4.
9. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994;74 (8):2276-80.
10. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, Klijn JGM. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-5.
11. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hoffer H, Graeff H. Urokinase (uPA), its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;224:195-208.
12. Fernö M, Bendahl PO, Börg A, Brundell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong and independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996;32A:793-801.
13. Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 1992;28A:1780-3.
14. Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rousse J, Maudelonde T, et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989;2:1115-8.
15. Tandon AK, Clarke GM, Chamness GC, Chirgwin J, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
16. Westly BR, May FEB. Cathepsin D and breast cancer. Eur J Cancer 1996;32A:15-24.
17. Duffy MJ. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin Biochem 1993;26:439-47.
18. Gasparini G, Pozza F, Harris A. Evaluating the potential usefulness of new prognostic and predictive indicators in node negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-19.
19. Foekens JA, Berns EMJJ, Look MP, Klijn JGM. Prognostic factors in node-negative breast cancer. In: Pasqualini JR, Katzenellenbogen BS, eds. Hormone dependent cancers. New York: Marcel Decker, 1996:217-53.
20. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer M, Jänicke F, Klijn JGM. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12: 1648-58.
21. Clarke GM. Do we really need prognostic markers in breast cancer? Breast Cancer Res Treat 1994;30:117-26.
22. Foekens JA, Look M, Peters HA, van Putten WLJ, Portengen H, Klijn JGM. Urokinase plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995;87:751-6.
23. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:154-5.
24. Blankenstein MA. Biochemical assessment of tissue prognostic factors in breast cancer. Breast 1997;6:31-7.
25. Benraad ThJ, Guerts-Moespot J, Grøndahl-Hansen J, Schmitt M, Heuval J, de Witte JH, et al. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EROTC/Biomed workshop. Eur J Cancer 1996;32A:1371-81.